Literature DB >> 30473435

The impact of gynaecological cancer treatment on physical activity levels: a systematic review of observational studies.

Kuan-Yin Lin1, Lara Edbrooke2, Catherine L Granger3, Linda Denehy2, Helena C Frawley4.   

Abstract

BACKGROUND: The natural history of physical activity levels during and following gynaecological cancer treatment is not well understood. This is required in order to establish the time at which physical activity levels are lowest in order to target cancer rehabilitation or exercise interventions in gynaecological cancer population accordingly.
OBJECTIVES: To conduct a systematic review to evaluate the impact of gynaecological cancer treatments on physical activity levels and to summarise the pattern of changes in physical activity levels over time among patients with gynaecological cancer.
METHODS: A comprehensive literature search was performed via MEDLINE (1946-2018), CINAHL (1982-2018), EMBASE (1947-2018), Ovid Emcare (1947-2018), PsycINFO (1806-2018) and the Cochrane Library (1991-2018). Studies were eligible for inclusion if they had assessed changes in physical activity levels during and after gynaecological cancer treatment. The methodological quality of the eligible studies was assessed by two independent reviewers using the Joanna Briggs Institute Critical Appraisal Tools.
RESULTS: In total, six studies (three cohort studies and three cross-sectional studies) with 1607 participants were included. All studies used patient-reported physical activity measures. Two of the three cohort studies measured patient-recalled physical activity levels before diagnosis (baseline), and length of follow-up varied across all studies. The majority of participants were treated surgically±adjuvant therapy. Physical activity levels decreased at 6 months following surgery when compared with pre-treatment levels. Approximately 91% of participants did not meet physical activity guidelines 2 years following diagnosis, and 58% reported being less physically active 3 years after diagnosis, compared with the pre-diagnosis levels.
CONCLUSIONS: Despite the paucity of evidence and limitations in the current body of literature, this review demonstrated that compared to pre-diagnosis, levels of physical activity remain low in gynaecological cancer survivors up to 3 years after diagnosis. More research is warranted to better characterise the pattern of change of physical activity levels across the disease trajectory and identify changes in physical activity patterns by cancer treatments and gynaecological tumour streams in order to target interventions accordingly.
Copyright © 2019 Associação Brasileira de Pesquisa e Pós-Graduação em Fisioterapia. Publicado por Elsevier Editora Ltda. All rights reserved.

Entities:  

Keywords:  Gynaecological cancer; Ovarian cancer; Physical activity; Physical therapy; Rehabilitation; Systematic review

Mesh:

Year:  2018        PMID: 30473435      PMCID: PMC6429005          DOI: 10.1016/j.bjpt.2018.11.007

Source DB:  PubMed          Journal:  Braz J Phys Ther        ISSN: 1413-3555            Impact factor:   3.377


  3 in total

1.  An allied health rehabilitation program for patients following surgery for abdomino-pelvic cancer: a feasibility and pilot clinical study.

Authors:  Helena C Frawley; Kuan-Yin Lin; Catherine L Granger; Rosemary Higgins; Michael Butler; Linda Denehy
Journal:  Support Care Cancer       Date:  2019-06-27       Impact factor: 3.603

Review 2.  Postoperative health-related quality of life of patients with gynecological malignancy: a meta-analysis.

Authors:  Se-Ge Ma; Xue Deng; Lu Xing; Yan Huang
Journal:  Support Care Cancer       Date:  2021-02-17       Impact factor: 3.603

3.  Cancer-related psychosocial factors and self-reported changes in lifestyle among gynecological cancer survivors: cross-sectional analysis of PROFILES registry data.

Authors:  Karin A J Driessen; Belle H de Rooij; M Caroline Vos; Dorry Boll; Johanna M A Pijnenborg; Meeke Hoedjes; Sandra Beijer; Nicole P M Ezendam
Journal:  Support Care Cancer       Date:  2021-08-28       Impact factor: 3.359

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.